PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver - Pediatric
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Drug Studies
Contact Us
Log In
You need to enable JavaScript to run this app page.
Breast
HCI-027
Model Details
Patient
PDX Model
Drug Studies
Histology
Metastasis
Patient Treatment
Patient Information for Model: HCI-027
Contact Model Developer
Model Contact
Model: HCI-027
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email:
Alana.Welm@hci.utah.edu
Patient Information
Clinical Timeline
Color Keys:
Positive
Negative
N/A
Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection
Model Information for Model: HCI-027
Model Details - Initial Implantation of Patient Tissue
Biomarkers & Mutations
Model Details - Acceptable Conditions for Passaging
Mutations (Cancer Gene Census List)
Mutation data is currently not available.
CNV
There are no omics data for this model.
Drug Studies for Model: HCI-027
Treatment Response Across All Studies
CR <=-95% to -100%
PR <-30% to >-95%
SD >=-30% to +20%
PD >=+20%
NA
Drug Study: T123-T130
Study Metadata
Study ID:
T123-T130
Study Type:
Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms:
2
Mouse Strain:
PI:
Alana Welm
Study Title:
Tolinapant Efficacy Study
Treatments:
Tolinapant
Study Duration:
Transplant Site
Transplant Material:
Study Design
Total arms showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Study Description
Arm Type
Treatment Arms
Number of Mice
Dose (mg/kg)
Concentration (mg/ml)
Vehicle
Route
Dosing Schedule
Control
Vehicle
Treatment
Tolinapant
20
Total arms showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Results
Total treatment results showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Arm
Treatment Duration
Monitoring Method
Monitor Duration
Tumor volume over time (%)
Response Category
Vehicle
21
836
PD
Tolinapant
21
127
PD
Total treatment results showing: 2
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Drug Study: Legacy2017
Study Metadata
Study ID:
Legacy2017
Study Type:
Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms:
16
Mouse Strain:
PI:
Alana Welm
Study Title:
Legacy 2017 - PDX Efficacy Study
Treatments:
5-Fluorouracil, MK-1775, Olaparib, Ponatinib, Doxorubicin, AZD8186, Palbociclib, TAK228, Palbociclib+AZD8186, Palbociclib+TAK228, Apitilosib, Everolimus, Gemcitabine, Paclitaxel, Lapatinib
Study Duration:
Transplant Site
Transplant Material:
Study Design
Total arms showing: 6
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Study Description
Arm Type
Treatment Arms
Number of Mice
Dose (mg/kg)
Concentration (mg/ml)
Vehicle
Route
Dosing Schedule
Treatment
Paclitaxel
3
20
Control
Vehicle
4
Treatment
Doxorubicin
4
10
Treatment
Lapatinib
3
200
Treatment
Gemcitabine
4
50
Treatment
Everolimus
4
5
Total arms showing: 6
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Results
Total treatment results showing: 6
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Arm
Treatment Duration
Monitoring Method
Monitor Duration
Tumor volume over time (%)
Response Category
Paclitaxel
21
32
PD
Vehicle
21
372
PD
Doxorubicin
21
-11
SD
Lapatinib
21
53
PD
Gemcitabine
21
56
PD
Everolimus
21
19
SD
Total treatment results showing: 6
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Histology Information for Model: HCI-027
There are no histology images for this model.
Metastasis Information for Model: HCI-027
Patient
PDX
Abdomen
Adrenal gland
Bone
Bone (de novo)
Bones
Brain
CTC
Chest
Chest wall
Contralateral Breast
Dura
Fallopian Tubes
Head
Kidney
LMD
Liver
Lung
Lymph node
Lymph nodes
Neck
None
Ovary
Pancreas
Pericardium
Peritoneal cavity
Peritoneum
Pleura
Pleural effusion
Shoulder
Skin
Spine
Spleen
Thoracic Spine
Thymus
medistinal and right hilar
Patient Treatment Information for Model: HCI-027
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
Clinical Response
10
Neo-adjuvant NAC Trial 6 cycles
Neoadjuvant
44.67
45.01
124 days
Progressive disease
20
Radiation Therapy to left chest wall
Adjuvant
45.08
45.16
29 days
Progressive disease
25
Radiation Therapy to left supraclavicula, right axilla and supraclavicular
Adjuvant
45.25
45.33
29 days
30
Carboplatin
Adjuvant
45.41
45.5
33 days
Progressive disease
Please wait...
